LikeMinds is a Boston-based dopamine transporter (DAT) imaging company. The LikeMinds team previously developed Neupro®, the world’s first transdermal movement disorder drug for Parkinson’s and Restless Legs Syndrome. LikeMinds has assembled a globally recognized board of directors, board of advisors and strategic collaborators. Utilizing proprietary DAT imaging and machine learning, LikeMinds will revolutionize the way doctors and pharmaceutical companies predict, diagnose, monitor and treat dopamine-related diseases. Someday, doctors will detect dopamine-mediated diseases years before the first symptoms, thereby enabling early medical intervention. Our mission is to help make someday happen sooner.